Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients

Respiratory Research

Table 1 Demographic and clinical characteristics at baseline

Parameters	Total (N = 54)
Age, years, median (range)	48 (26–70)
Sex, n (%)
Men	18 (33.3)
Women	36 (66.7)
Body mass index (kg/m²)	29.9 ± 5.1
Race, n (%)	Black 7 (13.0)
Race, n (%)	White 47 (87.0)
Ethnicity, n (%)	Hispanic or Latino 8 (14.8)
	Not Reported 30 (55.6)
	Unknown 8 (14.8)
	Other 8 (14.8)
Pre-bronchodilator FEV₁, L	2.229 ± 0.679
Post-bronchodilator FEV₁, L	2.693 ± 0.816
Pre-bronchodilator FEV₁, % predicted	71 ± 11
Post-bronchodilator FEV₁, % predicted	86 ± 12
FEV₁ Reversibility^a, L	0.464 ± 0.241
FEV₁ Reversibility^b (%)	21 ± 10

Data are represented as mean ± SD unless otherwise specified
FEV₁ Forced expiratory volume in 1 s, SD Standard deviation
^a Reversibility (L) is calculated as: FEV₁ (post-bronchodilator) - FEV₁ (pre-bronchodilator)
^b Reversibility (%) is calculated as: (FEV₁ (post-bronchodilator) - FEV₁ (prebronchodilator) × 100)/ FEV₁ (prebronchodilator)

ISSN: 1465-993X